- Conditions
- Aging, Benzodiazepine Sedative Adverse Reaction, Anticholinergic Adverse Reaction, Adverse Drug Event
- Interventions
- Follow-up booster Alert, Pre-commitment, Enhanced Alert
- Other
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 1,012
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Birth Outcomes, Safety, Adverse Event Following Immunization
- Interventions
- mRNA COVID-19 vaccine, IIV4 (quadrivalent inactivated influenza vaccine)
- Biological
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 98 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 6
- States / cities
- Atlanta, Georgia • Boston, Massachusetts • Durham, North Carolina + 2 more
- Conditions
- Coronary Microvascular Dysfunction, Cardiotoxicity, Breast Cancer, Lung Cancer (NSCLC)
- Interventions
- Not listed
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Leukemia
- Interventions
- Dexamethosone
- Drug
- Lead sponsor
- National Institute of Nursing Research (NINR)
- NIH
- Eligibility
- 5 Years to 21 Years
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2006
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Migraine
- Interventions
- Ubrogepant, Placebo for Ubrogepant
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 496 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 103
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 92 more
- Conditions
- Carcinoid Syndrome
- Interventions
- Xermelo
- Drug
- Lead sponsor
- TerSera Therapeutics LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 223 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Research Triangle Park, North Carolina
- Conditions
- Cardiovascular Risk, Obesity
- Interventions
- Zenagamtide, Placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 8,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 155
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 134 more
- Conditions
- Ototoxicity, Unspecified Adult Solid Tumor
- Interventions
- alpha-lipoic acid, Audiology, laboratory biomarker analysis, Placebo
- Drug · Behavioral · Biological
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 2
- States / cities
- Portland, Oregon
- Conditions
- Peripheral Arterial Occlusion or Emboli
- Interventions
- Mechanical Thrombectomy by the Indigo System
- Device
- Lead sponsor
- Penumbra Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 5
- States / cities
- San Diego, California • Miami, Florida • Chicago, Illinois + 2 more
- Conditions
- Non-hodgkin Lymphoma, Multiple Myeloma
- Interventions
- Audio Tasks
- Diagnostic Test
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 8
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Anemia, Breast Cancer, Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- epoetin alfa, placebo
- Biological · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 344 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2010
- U.S. locations
- 20
- States / cities
- Scottsdale, Arizona • Washington D.C., District of Columbia • Peoria, Illinois + 17 more
- Conditions
- Intubation Complication, Adverse Events
- Interventions
- tracheal intubation
- Other
- Lead sponsor
- Thomas Riva
- Other
- Eligibility
- Up to 16 Years
- Enrollment
- 105,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Philadelphia, Pennsylvania
- Conditions
- Lymphoma, Childhood Lymphoma, Solid Tumor, Childhood Solid Tumor, Neuroblastoma, Ewing Sarcoma, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Rhabdomyosarcoma, Soft Tissue Sarcoma, Medulloblastoma, Germ Cell Tumor, Wilms Tumor, Brain Neoplasms, Medulloblastoma, Childhood, Neuroectodermal Tumors, Primitive
- Interventions
- Genistein, Placebo
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Childhood Cancer, Cardiac Toxicity, Pediatric Cancer
- Interventions
- Computerized Intervention Authoring Software (CIAS)
- Behavioral
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Schizophrenia
- Interventions
- Folic Acid, Placebo
- Dietary Supplement · Other
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2019
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Infusion Reactions
- Interventions
- unlicensed CBU
- Biological
- Lead sponsor
- New York Blood Center
- Other
- Eligibility
- Not listed
- Enrollment
- 9,999 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2030
- U.S. locations
- 71
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more
- Conditions
- Pain
- Interventions
- buprenorphine and low-dose naloxone, buprenorphine alone
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Eosinophilic Gastritis (EoG), Eosinophilic Duodenitis (EoD), Eosinophilic Gastrointestinal Disease (EGID), Eosinophilic Gastroenteritis
- Interventions
- Dupilumab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 36
- States / cities
- Phoenix, Arizona • Apple Valley, California • La Jolla, California + 31 more
- Conditions
- Parkinson Disease
- Interventions
- Continuous Release Dopamine Agonists
- Drug
- Lead sponsor
- University of Toledo
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Toledo, Ohio
- Conditions
- Healthy Volunteers
- Interventions
- Emraclidine
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Grayslake, Illinois
- Conditions
- Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm
- Interventions
- Anti-PD-L1 Monoclonal Antibody, Anti-PD1 Monoclonal Antibody, Biopsy, Biospecimen Collection, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Quality-of-Life Assessment, Siltuximab
- Biological · Procedure · Other
- Lead sponsor
- Yuanquan Yang
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Patient Readmission, Adverse Drug Event, Cost
- Interventions
- HIE Notification, Care transitions intervention
- Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 65 Years and older
- Enrollment
- 796 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana • The Bronx, New York
- Conditions
- Glabellar Lines
- Interventions
- AGN-151586
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 992 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Los Angeles, California + 36 more
- Conditions
- Congestive Heart Failure
- Interventions
- I-123 mIBG
- Drug
- Lead sponsor
- GE Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 471 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Princeton, New Jersey